The non ergot D2-dopamine agonist CV 205-502 decreases growth hormone concentrations in acromegalic patients. 1994

T Svoboda, and H Kotzmann, and M Clodi, and P Bernecker, and G Geyer, and A Luger
Department of Medicine III, University of Vienna, Austria.

It was the aim of this study to test for a possible effect of the new non ergot dopamine agonist CV 205-502 on plasma growth hormone (GH) concentrations in acromegaly. 10 acromegalic patients received a single oral dose of 150 micrograms CV 205-502 after an overnight fast. As a control group 7 acromegalic patients undertook the same procedure without receiving any drug. Blood samples were drawn hourly up to 7 hours thereafter for determination of GH. Plasma growth hormone concentrations decreased by 48.8 +/- 8.7%. The nadir was observed 3 hours after CV 205-502 was administered and GH concentrations remained suppressed throughout the 7 hours of the test period. In contrast GH plasma concentrations in the control group remained stable. We conclude that acute administration of CV 205-502 suppresses GH secretion in acromegalic patients and thus could serve as an alternative therapy in acromegaly.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000172 Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) Inappropriate Growth Hormone Secretion Syndrome (Acromegaly),Somatotropin Hypersecretion Syndrome (Acromegaly),Inappropriate GH Secretion Syndrome (Acromegaly),Hypersecretion Syndrome, Somatotropin (Acromegaly),Hypersecretion Syndromes, Somatotropin (Acromegaly),Somatotropin Hypersecretion Syndromes (Acromegaly),Syndrome, Somatotropin Hypersecretion (Acromegaly),Syndromes, Somatotropin Hypersecretion (Acromegaly)
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000634 Aminoquinolines Quinolines substituted in any position by one or more amino groups.
D013006 Growth Hormone A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. Growth Hormone, Recombinant,Pituitary Growth Hormone,Recombinant Growth Hormone,Somatotropin,Somatotropin, Recombinant,Growth Hormone, Pituitary,Growth Hormones Pituitary, Recombinant,Pituitary Growth Hormones, Recombinant,Recombinant Growth Hormones,Recombinant Pituitary Growth Hormones,Recombinant Somatotropins,Somatotropins, Recombinant,Growth Hormones, Recombinant,Recombinant Somatotropin
D015259 Dopamine Agents Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. Dopamine Drugs,Dopamine Effect,Dopamine Effects,Dopaminergic Agents,Dopaminergic Drugs,Dopaminergic Effect,Dopaminergic Effects,Agents, Dopamine,Agents, Dopaminergic,Drugs, Dopamine,Drugs, Dopaminergic,Effect, Dopamine,Effect, Dopaminergic,Effects, Dopamine,Effects, Dopaminergic

Related Publications

T Svoboda, and H Kotzmann, and M Clodi, and P Bernecker, and G Geyer, and A Luger
January 1990, Movement disorders : official journal of the Movement Disorder Society,
T Svoboda, and H Kotzmann, and M Clodi, and P Bernecker, and G Geyer, and A Luger
May 1990, Annals of internal medicine,
T Svoboda, and H Kotzmann, and M Clodi, and P Bernecker, and G Geyer, and A Luger
March 1991, British journal of obstetrics and gynaecology,
T Svoboda, and H Kotzmann, and M Clodi, and P Bernecker, and G Geyer, and A Luger
May 1995, European journal of endocrinology,
T Svoboda, and H Kotzmann, and M Clodi, and P Bernecker, and G Geyer, and A Luger
September 1988, Clinical endocrinology,
T Svoboda, and H Kotzmann, and M Clodi, and P Bernecker, and G Geyer, and A Luger
April 1992, Biochemical pharmacology,
T Svoboda, and H Kotzmann, and M Clodi, and P Bernecker, and G Geyer, and A Luger
April 1994, Clinical endocrinology,
T Svoboda, and H Kotzmann, and M Clodi, and P Bernecker, and G Geyer, and A Luger
February 1988, Brain research,
T Svoboda, and H Kotzmann, and M Clodi, and P Bernecker, and G Geyer, and A Luger
December 1990, The Journal of clinical endocrinology and metabolism,
T Svoboda, and H Kotzmann, and M Clodi, and P Bernecker, and G Geyer, and A Luger
May 1990, Clinical endocrinology,
Copied contents to your clipboard!